Clene Reports Q1 2026 Net Loss Widens to $8.09M on Just $15K Revenue
CLNN has more than doubled off its 52-week low of $2.28 on light trading volume (0.3× avg).
Summary
Clene Inc. reported a significant widening of its net loss to $8.09 million in Q1 2026, a substantial increase from $751,000 in the prior year, alongside negligible revenue of just $15,000. This financial update, derived from the company's 10-Q filing, highlights a high cash burn rate. While the company recently announced positive FDA feedback for its ALS drug and completed a $7 million public offering, these Q1 results underscore the critical need for that capital to sustain operations and ongoing clinical development. The net loss represents a significant portion of the company's market capitalization for the quarter. Traders will be closely watching the company's cash runway and future financing needs as it progresses towards a planned NDA filing in Q3 2026 and a Phase 3 confirmatory study in Q1 2027.
At the time of this announcement, CLNN was trading at $6.50 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $76.6M. The 52-week trading range was $2.28 to $13.50. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: Wiseek News.